Both albiglutide and dulaglutide received FDA approval for the treatment of T2DM in 2014, with dulaglutide having an additional indication since 2020 to reduce the risk of major adverse cardiovascular events (MACE) in adults with T2DM and established cardiovascular disease or multiple cardiovascular risk factors [ Table 2 ]
For reference, tirzepatide costs approximately $1,060 CAD monthly in the United States without insurance, while semaglutide runs around $1,350 CAD monthly
Moffat et al., 1996
Unlike the acute setting, however, prolonged ablation of GSH synthesis in the liver resulted in decreased abundance of epididymal white adipose depots, a major storage tissue for triglycerides (Fig
Bu, T., Sun, Z., Pan, Y., Deng, X., & Yuan, G
GLP-1 use in the U.S